Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$10.16 - $13.11 $1.14 Million - $1.48 Million
-112,519 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$9.04 - $11.86 $648,818 - $851,215
-71,772 Reduced 38.94%
112,519 $1.26 Million
Q4 2020

Feb 16, 2021

BUY
$9.05 - $12.2 $153,850 - $207,400
17,000 Added 10.16%
184,291 $2.1 Million
Q3 2020

Nov 04, 2020

BUY
$8.99 - $10.74 $385,671 - $460,746
42,900 Added 34.49%
167,291 $1.51 Million
Q2 2020

Jul 31, 2020

BUY
$9.14 - $11.97 $92,314 - $120,897
10,100 Added 8.84%
124,391 $1.28 Million
Q1 2020

May 08, 2020

SELL
$8.58 - $14.01 $90,948 - $148,506
-10,600 Reduced 8.49%
114,291 $1.15 Million
Q4 2019

Feb 11, 2020

SELL
$8.22 - $14.0 $67,404 - $114,800
-8,200 Reduced 6.16%
124,891 $1.66 Million
Q3 2019

Nov 01, 2019

SELL
$8.59 - $10.96 $2,577 - $3,288
-300 Reduced 0.22%
133,091 $1.14 Million
Q2 2019

Aug 13, 2019

BUY
$9.8 - $12.89 $803,325 - $1.06 Million
81,972 Added 159.42%
133,391 $1.46 Million
Q1 2019

May 15, 2019

SELL
$8.27 - $12.73 $4.32 Million - $6.65 Million
-522,000 Reduced 91.03%
51,419 $695,000
Q1 2019

May 13, 2019

BUY
$8.27 - $12.73 $4.32 Million - $6.65 Million
522,500 Added 1026.14%
573,419 $1.27 Million
Q4 2018

Feb 14, 2019

SELL
$7.8 - $16.13 $41,730 - $86,295
-5,350 Reduced 9.51%
50,919 $528,000
Q3 2018

Nov 14, 2018

BUY
$14.31 - $17.65 $111,618 - $137,670
7,800 Added 16.09%
56,269 $1.04 Million
Q2 2018

Aug 06, 2018

SELL
$11.83 - $16.2 $92,274 - $126,360
-7,800 Reduced 13.86%
48,469 $927,000
Q1 2018

May 03, 2018

BUY
$11.13 - $13.63 $626,273 - $766,946
56,269 New
56,269 $868,000

Others Institutions Holding IRWD

About IRONWOOD PHARMACEUTICALS INC


  • Ticker IRWD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 153,231,008
  • Market Cap $541M
  • Description
  • Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...
More about IRWD
Track This Portfolio

Track Mackay Shields LLC Portfolio

Follow Mackay Shields LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mackay Shields LLC with notifications on news.